

1 *U-shaped Association Between Mean Platelet Volume And Short-term*
2 *Survival In Chinese Patients With Heart Failure*

3 Yuan-lei Huang^a, Qi Zhou^a, Tao Zheng^{a*}

4 The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang,
5 China

6 Yuan-lei Huang

7 Department: Department of Cardiovascular Medicine

8 Hospital: The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine

9 Street Name & Number: No.50, North Baoshan Road, Yunyan District, Guizhou Province

10 Qi Zhou

11 Department: Department of Cardiovascular Medicine

12 Hospital: The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine

13 Street Name & Number: No.50, North Baoshan Road, Yunyan District, Guizhou Province

14 Corresponding Author:

15 Tao Zheng

16 Department: Department of Cardiovascular Medicine

17 Hospital: The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine

18 Street Name & Number: No.50, North Baoshan Road, Yunyan District, Guizhou Province

19 Tel:8615985184796

20 E-mail: oulaosionzhengtao@163.com

21

22

23

24

25

26 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

27 **Keywords:** Mean platelet volume, Association, Nonlinearity, Non-obese, 6 months all-cause
28 mortality

29 **Background:** Mean Platelet Volume (MPV) has been proposed as a potential predictor of
30 increased mortality risk at 6 months among Chinese patients with heart failure (HF). However, the
31 current evidence supporting this association is limited.

32 **Methods:** This study aimed to investigate the relationship between MPV and HF short-term
33 survival status. The data was obtained from a publicly accessible HF database in Zigong, Sichuan,
34 and included information on 2008 Chinese patients. Baseline MPV was considered as the
35 exposure while HF short-term survival status was the outcome. Two models, a binary logistic
36 regression model and a two-piecewise linear model, were used to analyze the data.

37 **Results:** The study revealed a U-shaped relationship between MPV and all-cause mortality in
38 HF patients. When MPV levels were less than 9.8, every unit increase in MPV was associated
39 with a 91% reduction (RR: 0.09; 95% CI: 0.03-0.24; P=0.0001) in the risk of death over the next
40 six months. In contrast, at MPV levels above 9.8, each unit increase in MPV was linked to a 27%
41 increase (RR: 1.27; 95% CI: 1.01-1.61; P=0.0434) in the probability of dying within the same
42 period. Stratification by obesity status revealed no significant association between MPV and death
43 in the obese population, while the same U-shaped association was observed among non-obese
44 participants.

45 **Conclusion:** The present study provides evidence of a U-shaped association between MPV
46 and short-term survival in Chinese patients with heart failure. These findings suggest that MPV
47 may serve as a potential prognostic marker for HF. However, further studies are needed to validate
48 these results and to explore the underlying mechanisms of this association. The observed U-
49 shaped association did not apply to obese patients, suggesting that the effect of MPV on mortality
50 risk in HF patients may be influenced by body weight.

51

52 **Introduction**

53 The mean platelet volume (MPV) is a low-cost and easy-to-use blood count indicator that has
54 been suggested to play a critical role in platelet reactivity, inflammation, thrombosis, and heart
55 failure (HF) in previous studies(1-4). MPV is frequently used as a surrogate measure of platelet
56 function since it reflects both platelet size and activity, with larger platelets being associated with
57 increased platelet aggregation, thromboxane production, platelet globulin release, and adhesion
58 molecule expression(5). Elevated MPV levels have been found in various disease states,
59 particularly in individuals with cardiovascular risk factors such as smoking, diabetes, obesity,
60 hypertension, and hyperlipidemia (6-10), indicating a need for careful cardiovascular risk
61 assessment (11). Excessively high MPV levels are also associated with increased cardiovascular
62 disease risk and a poor prognosis.

63 HF is a worldwide pandemic disease that affects at least 26 million people worldwide and is
64 increasing in prevalence as the population ages(12). In China, the number of people suffering from
65 HF has risen to 1.3 percent of the entire population(13). HF not only affects patients' quality of
66 life, but it also has a substantial financial impact on their families and society. According to
67 figures, HF accounts for 17 percent of total health expenditures for cardiovascular illness in the
68 United States(14), and total expenses are expected to rise by 127 percent between 2012 and
69 2030(15). Given the high mortality rate as well as the high financial burden caused by HF,
70 researchers have called HF "the last war of cardiovascular disease in the 21st century."(16, 17)

71 In recent years, MPV has piqued interest as a novel prognostic marker in patients with
72 cardiovascular illness. However, evidence linking MPV to all-cause mortality in HF is lacking.
73 Budak et al. discovered a positive correlation between BNP and MPV(18). Furthermore,
74 Kaya (19) and Kandis(2) reported that MPV upon admission was highly linked to in-hospital
75 mortality or death at 6 months, even after controlling for typical HF-related risk variables.
76 However, the majority of the information presented above has come from Western countries.
77 Besides, evidence on the link between MPV and short-term mortality in patients with HF in the
78 Chinese population is limited. Given China's vast population and rising HF prevalence, a better
79 understanding of the relationship between MPV and short-term mortality risk in HF will be
80 beneficial for future predictive model-driven investigations. In light of this, this study offers a
81 secondary data analysis of a large sample HF database to investigate the relationship between
82 MPV and HF short-term prognosis. This study will also reveal these results.

83

84 **Participants and methods**

85 **Data source and study design**

86 This study is a retrospective cohort analysis based on publicly available and published data
87 obtained from clinical records of hospitalized inpatients with confirmed heart failure (HF) at the
88 Fourth People's Hospital in Zigong City, Sichuan Province, China, between December 2016 and
89 June 2019. The data was downloaded from the PhysioNet website (10.13026/8a9e-w734), and a
90 detailed description of the dataset is available in the literature(20). The dataset has been de-
91 identified to protect patient privacy. All data were extracted from the hospital's electronic medical
92 record system, and the Ethics Committee of the Fourth People's Hospital of Zigong approved the
93 study (approval number: 2020-010). Patient informed consent was not required due to the
94 retrospective nature of the study and the anonymization of patient information. The outcome
95 variable was 6-month all-cause mortality in HF patients, recorded as a dichotomous variable in the
96 original data, and the target independent variable was baseline MPV, recorded as a continuous
97 variable.

98 **Study population**

99 A sample of 2,008 individuals with HF was initially included in the dataset; however, after
100 applying a set of screening criteria, 103 cases were excluded due to missing MPV data, leaving
101 1,905 cases for data analysis (for details, refer to Figure 1). The diagnosis of HF was made based
102 on the criteria established by the European Society of Cardiology (ESC), and ICD codes were
103 used to collect data on heart failure. The data provider has furnished specific details on the dataset.

104 **Variables**

105 **Mean platelet volume**

106 The mean platelet volume (MPV) was initially recorded as a continuous variable in the raw
107 data. However, to investigate the stability of the results and ensure the robustness of the findings,
108 we further transformed the MPV into a categorical variable based on quartiles. Specifically, the
109 data was divided into four subgroups: Q1 (MPV range: 7.70-10.80, n=475), Q2 (MPV range:
110 10.90-12.00, n=475), Q3 (MPV range: 12.10-13.20, n=476), and Q4 (MPV range: 13.30-17.60,
111 n=479). This approach allowed us to examine whether the effect values varied equidistantly and to
112 compare the consistency of the results obtained using MPV as a continuous versus a categorical
113 variable.

114 **6-month all-cause death in HF patients**

115 The primary outcome measure of this study was six-month all-cause mortality in HF patients.
116 The original dataset provided information on the survival of HF patients at 6 months, represented
117 by a binary variable where 0 indicates survival and 1 indicates death.

118 **Covariates**

119 In this analysis, potential confounding variables were selected based on prior literature (21-
120 23) that investigated risk factors associated with adverse outcomes in HF, as well as our clinical
121 experience. The following variables were included: age and gender as demographic factors,
122 Charlson Comorbidity Index (CCI) as a measure of co-morbidities, statins, vasodilators, Ras
123 blockers, and positive inotropes as pharmaceutical factors, high-sensitivity troponin, glomerular
124 filtration rate, and BNP as biomarkers, and BMI, NYHY classification, and number of
125 hospitalizations as illness features and anthropometric factors.

126 **Statistical analysis**

127 Continuous variables were expressed as mean \pm standard deviation (SD) (Gaussian
128 distribution) or median (range) (skewed distribution), and categorical variables were expressed as
129 numbers and percentages. The χ^2 (categorical variables), one-way ANOVA test (normal
130 distribution), or Kruskal-Whallis H test (skewed distribution) were used to detect differences in
131 the distribution of baseline information across MPV subgroups (quartiles). We examined
132 univariate and multivariate binary logistic regression models to determine the association between
133 the two. To observe the stability of changes in effect values under multiple strategy alterations, we
134 simultaneously display three models. The unadjusted model, or Model 1, does not account for
135 covariates. The model with the fewest adjustments simply for sociodemographic components is
136 Model 2. Model 3 was the one that was completely factor-adjusted. because the binary logistic
137 regression model was unable to account for the nonlinear relationships. We utilized a generalized
138 additive model (GAM) and a smoothed curve fit to examine whether MPV was nonlinearly related
139 to the probability of short-term death in HF (penalized spline method). If nonlinearity was
140 detected, we first used the recursive algorithm + bootstrapping to calculate the inflection point
141 extremely credible intervals, and then constructed two-piece binary logistic regression models on
142 both sides of the inflection point.

143 To illustrate the robustness of our results, we performed a sensitivity analysis. We
144 transformed mean platelet volume into a categorical variable based on quartiles and calculated p
145 for trend. The aim was to see whether the association with outcome was consistent when MPV
146 was used as a continuous variable versus when it was used as a categorical variable.

147 R (<http://www.r-project.org>, R Foundation) and EmpowerStats
148 (<http://www.empowerstats.com>, X & Y Solutions, Inc., Boston, MA) are statistical applications
149 that were utilized to model the data. Statistical significance was defined as p-values of 0.05 (two-
150 sided).

151

152 **Results**

153 **Baseline characteristics of participants**

154 Table 1 summarizes the baseline characteristics of all HF patients, categorized into quartiles
155 based on their MPV levels. Nearly 70% of the patients were below the age of 70. Significant
156 differences were observed between the various MPV level groups (Q1-Q4) for eGFR, Ln BNP,
157 age, sex, use of Ras-Blockers, Inotropes, and diuretics ($P < 0.05$). Compared to the Q4 group, the
158 Q1, Q2, and Q3 groups had lower eGFR, Ln hs-Tnl, and LnBNP levels, and a smaller percentage

159 of females, a greater percentage of individuals over 70, and a lower percentage of RAS blockers,
160 vasodilators, and diuretics. However, there was no statistically significant difference between the
161 Q1-Q4 groups in terms of BMI, Charlson comorbidity score, NYHA classification, Vasodilator
162 use, Statin use, number of hospitalizations, or 6-month all-cause mortality ($P > 0.05$).

163 **Results of a binary logistic regression model's multivariate analysis**

164 We employed a binary logistic regression model to examine the association between MPV
165 and the 6-month risk of death in HF patients. Our analysis did not reveal a significant relationship
166 between MPV and all-cause mortality (RR, 0.90; 95% CI: 0.77 to 1.06; $P=0.1920$). Furthermore,
167 the minimally-adjusted (RR, 0.90, 95% CI: 0.77 to 1.06; $P=0.2054$) and fully-adjusted (RR, 0.94,
168 95% CI: 0.78 to 1.13; $P=0.4888$) models yielded identical results despite different adjustment
169 procedures.

170 To verify the consistency of our findings, we categorized MPV into quartiles and calculated P
171 for trend to compare with the results obtained from MPV as a continuous variable. As shown in
172 Table 2, Our analysis revealed that RR had unequal variation across MPV subgroups (Q1-Q4),
173 and P for trend values were discordant with those obtained using MPV as a continuous variable.
174 These findings suggest that a non-linear relationship between MPV and all-cause mortality cannot
175 be excluded.

176 **Using generalized summation models to solve nonlinear issues**

177 We found that the association between MPV and short-term all-cause mortality in HF
178 patients was non-linear using a generalized summation model and smoothed curve fitting (Figure
179 2). A two-piecewise linear model was developed on both sides of the inflection point, which was
180 obtained using a recursive approach (Table 3). The non-linear results showed a U-shaped
181 relationship between MPV and 6-month mortality. Positive results were observed when MPV was
182 greater than 9.8 (RR, 1.27; 95% CI, 1.01 to 1.61), indicating that each 1fL increase in MPV was
183 associated with a 27% increase in the risk of death. Negative results were found when MPV was
184 less than 9.8 (RR, 0.09; 95% CI, 0.03 to 0.24), indicating that each 1fL increase in MPV was
185 associated with a 91% reduction in the risk of death. Additionally, we stratified the individuals
186 into different obesity categories and found no association between MPV and mortality in the obese
187 group. In contrast, in the non-obese population, the same U-shaped relationship between MPV and
188 6-month mortality was observed. At $MPV < 9.7$, the association between MPV and 6-month
189 mortality was negative (RR, 0.08; 95% CI, 0.03 to 0.22), indicating that each 1fL increase in MPV
190 was associated with a 92% reduction in mortality risk; at $MPV > 9.7$ 1fL, the association between
191 MPV and 6-month mortality was positive (RR, 1.29; 95% CI, 1.02 to 1.64), indicating that each
192 1fL increase in MPV was associated with a 29% increase in the risk of death.

193

194 **Discussion**

195 Our results imply that there is a U-shaped link between mean platelet volume and short-term
196 mortality in HF in this cohort study. Both low and high MPV levels were linked to higher all-
197 cause mortality in HF. However, this association did not hold true for obese individuals with HF.
198 This discovery offers a priori support for upcoming model-driven studies and may have
199 ramifications for how MPV levels are interpreted in clinical settings. As one of the most prevalent
200 clinical markers, understanding the true relationship between MPV and a poor prognosis in HF
201 will aid in the development of more accurate models. Our findings will also assist clinicians in
202 making a more precise early evaluation of a patient's future risk linked with MPV, even though

203 this initial assessment is just approximate. Additionally, compared to other markers (blood
204 glucose, potassium, etc.), which might alter as a result of various situations, MPV is a more stable
205 measure.

206 Dilated chambers, poor contractility, local ventricular wall abnormalities, and combined atrial
207 fibrillation may promote thromboembolism by facilitating intracardiac blood flow arrest, which is
208 one of the possible mechanisms of poor prognosis in HF given that MPV is known to be a strong
209 indicator of platelet activation and congestive HF is characterized by an increase in
210 thromboembolic events(24). According to Jafri(25) et al., the coagulation system and platelet
211 activation (increased plasma platelet factor 4, b-thromboglobulin) have been demonstrated to be
212 more susceptible in patients with severe HF and poor ejection fraction, The relationship between
213 platelet activation and a bad prognosis for HF stems from the possibility that these conditions may
214 contribute to the development of the disease by producing ischemic episodes, impairing left
215 ventricular function, and promoting intracardiac thrombosis. Chronic HF itself may increase the
216 risk of platelet abnormalities and thrombosis through increased catecholamine release,
217 haemodynamic changes, vascular factors, nitric oxide, cytokines, and comorbid conditions(26-28).
218 The increased cytokine and catecholamine release observed in patients with severe HF is
219 associated with platelet activation and higher levels of MPV. Therefore, by reducing excessive
220 catecholaminergic activity, some studies have reduced MPV levels in patients with HF, thereby
221 reducing mortality and hospitalization in HF(29, 30). In contrast, we discovered in our study that a
222 low MPV was likewise linked to a higher chance of passing away. The occurrence is currently
223 being reported for the first time, although no mechanisms have been found to explain it.
224 Additionally, we discovered various MPV and mortality trends across states with obesity. We
225 hypothesize that the absence of a correlation between the two in the obese group may be due to a
226 lesser correlation between MPV and mortality in this cohort and a larger correlation between BMI
227 and the risk of death. Of course, more data is required to support our findings given the tiny obese
228 population in our study.

229 While there are some similarities and some discrepancies between our results and those of
230 earlier studies(31, 32), they all point to the possibility of a higher MPV in HF. A previous
231 study(19) first demonstrated that MPV levels above 9.1 fL were an independent predictor of short-
232 to mid-term HF-related hospitalization in outpatients with stable HF rEF in SR. However, that
233 study had a small sample size and was restricted to HF patients with reduced ejection fraction,
234 whereas the current study was not. Kandis et al(2). conducted research. The best cutoff for
235 indicating elevated risk was > 10.5 fl. However, the cohort of patients in that study showed higher
236 levels of urea, serum creatinine, and systolic blood pressure in patients who passed away during
237 follow-up, suggesting a stronger impact of the patient's initial systolic blood pressure, BUN levels,
238 and creatinine. In a cohort study(33) of the condition, an MPV value of > 9 fL was discovered to
239 be a potential predictor of rehospitalization and 1-year mortality in patients with decompensated
240 chronic HF in a cohort study. However, the study's participants were those with decompensated
241 chronic HF who were hospitalized (NYHA class IV HF or acute pulmonary oedema). The study
242 has a limited sample size (n = 130) and no sensitivity analysis. By comparing the association
243 between the HF marker BNP and MPV, Budak et al. **Error! Reference source not found.** discovered that
244 MPV levels and brain natriuretic peptide (BNP) values were positively associated in patients
245 referred to the emergency room with acute HF. According to the scientists, MPV can be a sign of
246 the severity and clinical condition of acute HF disease. Taking into account study design,

247 demographics, and other characteristics, we think the following factors are responsible for the
248 results' variations.

249 Our clinical relevance can be seen in the following ways: The previous finding that high
250 MPV is strongly associated with a high risk of death in HF patients also holds true for the Chinese
251 population, according to our findings. In addition, we discovered that lower MPV is also strongly
252 associated with a high risk of death in HF patients, a finding that has never been previously
253 reported. This study suggests that in the future, doctors utilizing MPV as an assessment indicator
254 may need to include a patient's obesity status when making clinical judgments or first prognosis
255 assessments of patients. This offers fresh proof of MPV's clinical value.

256

257 **Study advantages and limitations**

258 We present a study with significant benefits, outlined below. Firstly, the use of large sample
259 sizes enhances our statistical power. Secondly, the covariate information in our data is highly
260 complete with few gaps. Thirdly, our work delves into non-linearity, providing further justification
261 and insight. In comparison to previous studies, this allows for a greater understanding of the
262 relationship between MPV and all-cause mortality. Lastly, we applied rigorous statistical
263 corrections to address potential confounding variables, given the observational nature of our study.

264 However, some limitations should be acknowledged. Firstly, we only utilized baseline MPV
265 measurements upon admission and were therefore unable to track MPV trends throughout
266 hospitalization and their impact on outcomes. Secondly, the study was geographically and racially
267 restricted to the Chinese population. Lastly, despite accounting for known potential confounders,
268 residual confounders may still exist in any observational study.

269 **Conclusion**

270 Our study investigated the association between baseline mean platelet volume and 6-month
271 all-cause mortality in patients with heart failure. We found a U-shaped association, where the all-
272 cause death rate increased at both low and high mean platelet volumes. However, we did not
273 observe this connection in the population with obesity-related heart failure. These results have
274 important clinical and public health implications, but additional prospective trials are needed to
275 validate our findings and clarify their clinical implications.

276

277 **Data Availability Statement**

278 Publicly available datasets were analyzed in this study. This data can be found here:
279 <https://doi.org/10.13026/8a9e-w734>.

280

281 **Ethics Statement**

282 Studies involving human subjects were reviewed and approved by the Ethics Committee of
283 the Fourth People's Hospital of Zigong. In accordance with national legislation and institutional
284 requirements, written informed consent for participation in this study was not required.

285

286 **Competing interests**

287 The authors declare that the research was conducted in the absence of any commercial or
288 financial relationships that could be construed as a potential conflict of interest. Funding

289

290 **Funding**

291 This study was funded by the Science and Technology Support Plan of Guizhou Provincial
292 Department of Science and Technology in 2020 (Project No. Qianke Support [2021] General 064).

293

294 Acknowledgments

295 We thank Chen Chi for their guidance and review of this manuscript.

296

297 Authors' Contributions

298 Y-LH collected documents and wrote the manuscript. QZ also contributed equally to this
299 work. Y-LH and QZ are co-first authors. TZ reviewed and performed critical revision of the
300 manuscript. All authors have read and agreed to the published version of the manuscript.

301

302 References :

303 1. Stokes KY, Granger DN. Platelets: a critical link between inflammation and microvascular

304 dysfunction. *J Physiol.* 2012;590(5):1023-34.

305 2. Kandis H, Ozhan H, Ordu S, Erden I, Caglar O, Basar C, et al. The prognostic value of mean

306 platelet volume in decompensated heart failure. *Emerg Med J.* 2011;28(7):575-8.

307 3. Kamath S, Blann AD, Lip GY. Platelets and atrial fibrillation. *Eur Heart J.* 2001;22(24):2233-

308 42.

309 4. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet

310 volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. *J Thromb*

311 *Haemost.* 2010;8(1):148-56.

312 5. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there

313 a practical index of platelet activity? *Clin Appl Thromb Hemost.* 2003;9(3):177-90.

314 6. Pathansali R, Smith N, Bath P. Altered megakaryocyte-platelet haemostatic axis in

315 hypercholesterolaemia. *Platelets.* 2001;12(5):292-7.

316 7. Nadar S, Blann AD, Lip GY. Platelet morphology and plasma indices of platelet activation in

317 essential hypertension: effects of amlodipine-based antihypertensive therapy. *Ann Med.*

318 2004;36(7):552-7.

319 8. Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in
320 elderly patients with risk factors for atherosclerosis. *Clin Lab Haematol.* 1992;14(4):281-7.

321 9. Inoue H, Saito M, Kouchi K, Asahara SI, Nakamura F, Kido Y. Association between mean
322 platelet volume in the pathogenesis of type 2 diabetes mellitus and diabetic macrovascular
323 complications in Japanese patients. *J Diabetes Investig.* 2020;11(4):938-45.

324 10. Coban E, Ozdogan M, Yazicioglu G, Akcıt F. The mean platelet volume in patients with
325 obesity. *Int J Clin Pract.* 2005;59(8):981-2.

326 11. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and
327 prognosis of cardiovascular diseases. *Int J Clin Pract.* 2009;63(10):1509-15.

328 12. Lund LH, Savarese G. Global Public Health Burden of Heart Failure. *Cardiac Failure Review.*
329 2017;03(01).

330 13. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. *Circ J.* 2013;77(9):2209-17.

331 14. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure:
332 preventing disease and death worldwide. *ESC Heart Fail.* 2014;1(1):4-25.

333 15. Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart
334 Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.

335 *Circulation.* 2016;133(4):e38-360.

336 16. Rohde LE, Bertoldi EG, Goldraich L, Polanczyk CA. Cost-effectiveness of heart failure
337 therapies. *Nat Rev Cardiol.* 2013;10(6):338-54.

338 17. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, et al. Survival of
339 patients with a new diagnosis of heart failure: a population based study. *Heart.* 2000;83(5):505-10.

- 340 18. Budak YU, Huysal K, Demirci H. Correlation between mean platelet volume and B-type
341 natriuretic peptide concentration in emergency patients with heart failure. *Biochem Med (Zagreb)*.
342 2015;25(1):97-102.
- 343 19. Kaya H, Kutay Yildirimli M, Kurt R, Beton O, Birhan Yilmaz M. Mean Platelet Volume as a
344 Predictor of Heart Failure-Related Hospitalizations in Stable Heart Failure Outpatients with Sinus
345 Rhythm. *Acta Cardiol Sin*. 2017;33(3):292-300.
- 346 20. Zhang Z, Cao L, Chen R, Zhao Y, Lv L, Xu Z, et al. Electronic healthcare records and external
347 outcome data for hospitalized patients with heart failure. *Sci Data*. 2021;8(1):46.
- 348 21. Wang R, Cao Z, Li Y, Yu K. Mean platelet volume provides an additive value in differentiating
349 congestive heart failure from chronic obstructive pulmonary disease. *Int J Cardiol*. 2015;179:201-2.
- 350 22. Dahlen B, Schulz A, Gobel S, Trobs SO, Schwuchow-Thonke S, Spronk HM, et al. The impact
351 of platelet indices on clinical outcome in heart failure: results from the MyoVasc study. *ESC Heart Fail*.
352 2021;8(4):2991-3001.
- 353 23. Cheng YL, Sung SH, Cheng HM, Hsu PF, Guo CY, Yu WC, et al. Prognostic Nutritional Index
354 and the Risk of Mortality in Patients With Acute Heart Failure. *J Am Heart Assoc*. 2017;6(6).
- 355 24. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary
356 intervention to prevent the readmission of elderly patients with congestive heart failure. *N Engl J*
357 *Med*. 1995;333(18):1190-5.
- 358 25. Moore EE, Moore HB, Kornblith LZ, Neal MD, Hoffman M, Mutch NJ, et al. Trauma-induced
359 coagulopathy. *Nat Rev Dis Primers*. 2021;7(1):30.
- 360 26. Stach K, Kalsch AI, Nguyen XD, Elmas E, Kralev S, Lang S, et al. 1alpha,25-dihydroxyvitamin
361 D3 attenuates platelet activation and the expression of VCAM-1 and MT1-MMP in human endothelial

362 cells. *Cardiology*. 2011;118(2):107-15.

363 27. Karabacak M, Dogan A, Aksoy F, Ozaydin M, Erdogan D, Karabacak P. Both carvedilol and
364 nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart
365 failure. *Angiology*. 2014;65(6):533-7.

366 28. Handtke S, Steil L, Greinacher A, Thiele T. Toward the Relevance of Platelet Subpopulations
367 for Transfusion Medicine. *Front Med (Lausanne)*. 2018;5:17.

368 29. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on
369 survival in severe chronic heart failure. *N Engl J Med*. 2001;344(22):1651-8.


370 30. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al.
371 Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital
372 admission in elderly patients with heart failure (SENIORS). *Eur Heart J*. 2005;26(3):215-25.

373 31. Martinez-Quintana E, Rodriguez-Hernandez JL, Riano-Ruiz M, Rodriguez-Gonzalez F. Mean
374 platelet volume and major adverse cardiovascular events in congenital heart disease patients. *Clin
375 Hemorheol Microcirc*. 2019;72(4):327-37.

376 32. Demirin H, Ozhan H, Ucgun T, Celer A, Bulur S, Cil H, et al. Normal range of mean platelet
377 volume in healthy subjects: Insight from a large epidemiologic study. *Thromb Res*. 2011;128(4):358-
378 60.


379 33. Andrei CL, Catana A, Sinescu CJ, Mirica A, Ceban O, Chioncel VP, et al. Mean Platelet
380 Volume: A Possible Predictor for Patients with Decompensated Chronic Heart Failure. *Int J Gen Med*.
381 2022;15:4131-40.

382



medRxiv preprint doi: <https://doi.org/10.1101/2023.06.16.23291510>; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1



medRxiv preprint doi: <https://doi.org/10.1101/2023.06.16.23291510>; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 1 : Baseline characteristics of patients with HF grouped by mean platelet volume(quartile)

	Q1(7.70-10.80)	Q2 (10.90-12.00)	Q3(12.10-13.20)	Q4 (13.30-17.60)	P-value
N	475	475	476	479	
BMI, mean±SD, kg/m ²	21.37 ± 9.58	21.40 ± 3.99	23.22 ± 25.08	21.37 ± 6.72	0.103
<small>medRxiv preprint doi: https://doi.org/10.1101/2023.06.16.23291510; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.</small>					
Obesity					
<28	452 (95.16%)	443 (93.26%)	442 (92.86%)	450 (93.95%)	
≥28	23 (4.84%)	32 (6.74%)	34 (7.14%)	29 (6.05%)	
Ln hs-Tnl , mean±SD	-2.86 ± 1.38	-2.78 ± 1.44	-2.73 ± 1.50	-2.98 ± 1.38	0.043
eGFR, mean±SD, mL/min/1.73 m ²	66.55 ± 38.66	66.27 ± 37.03	66.92 ± 34.53	73.62 ± 36.11	0.005
Ln BNP, mean±SD	6.33 ± 1.25	6.61 ± 1.25	6.59 ± 1.23	6.63 ± 1.19	<0.001
Charles comorbidity score,mean±SD	1.93 ± 0.92	1.86 ± 0.98	1.83 ± 0.96	1.83 ± 0.99	0.381
Sex, n (%)					0.034
Male	188 (39.58%)	207 (43.58%)	222 (46.64%)	183 (38.20%)	
Female	287 (60.42%)	268 (56.42%)	254 (53.36%)	296 (61.80%)	
Age, n (%)					0.003
≤70 years old	102 (21.47%)	120 (25.26%)	132 (27.73%)	152 (31.73%)	
>70 years old	373 (78.53%)	355 (74.74%)	344 (72.27%)	327 (68.27%)	

NYHA classification, n					0.655
	(%)				
II	80 (16.84%)	86 (18.11%)	82 (17.23%)	84 (17.54%)	
III	247 (52.00%)	237 (49.89%)	243 (51.05%)	265 (55.32%)	
IV	148 (31.16%)	152 (32.00%)	151 (31.72%)	130 (27.14%)	
Vasodilator use, n (%)					0.616
No	160 (33.68%)	164 (34.53%)	146 (30.67%)	156 (32.57%)	
Yes	315 (66.32%)	311 (65.47%)	330 (69.33%)	323 (67.43%)	
Ras-Blocker use, n (%)					<0.001
No	56 (11.79%)	25 (5.26%)	34 (7.14%)	25 (5.22%)	
Yes	419 (88.21%)	450 (94.74%)	442 (92.86%)	454 (94.78%)	
Inotropes use, n (%)					<0.001
No	159 (33.47%)	134 (28.21%)	111 (23.32%)	106 (22.13%)	
Yes	316 (66.53%)	341 (71.79%)	365 (76.68%)	373 (77.87%)	
Diuretic use, n (%)					0.002
No	16 (3.37%)	2 (0.42%)	10 (2.10%)	4 (0.84%)	
Yes	459 (96.63%)	473 (99.58%)	466 (97.90%)	475 (99.16%)	
Statin use, n (%)					0.514
No	271 (57.29%)	277 (58.44%)	293 (61.81%)	279 (58.25%)	
Yes	202 (42.71%)	197 (41.56%)	181 (38.19%)	200 (41.75%)	
Number of					0.254

medRxiv preprint doi: <https://doi.org/10.1101/2023.06.16.23291510>; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

hospitalizations, n (%)				
≤1	429 (90.32%)	440 (92.63%)	444 (93.28%)	447 (93.32%)
>1	46 (9.68%)	35 (7.37%)	32 (6.72%)	32 (6.68%)
6 months all-cause mortality, n (%)				
				0.374
Alive	457 (96.21%)	460 (96.84%)	467 (98.11%)	465 (97.08%)
Death	18 (3.79%)	15 (3.16%)	9 (1.89%)	14 (2.92%)

medRxiv preprint doi: <https://doi.org/10.1101/2023.06.16.23291510>; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Note: The difference between the sample sum of each column and the total number shown in

Table 1 is due to missing data

Abbreviation:

BMI: body mass index

Hs-Tnl: High-sensitivity troponin I

BNP: B-type natriuretic peptide

NYHA: New York Heart Association

eGFR: estimated glomerular filtration rate

Table 2: The association between MPV and all-cause mortality using binary logistic regression model

	Non-adjusted model	Minimally-adjusted model	Fully-adjusted model
	RR, 95%CI, P value	RR, 95%CI, P value	RR, 95%CI, P value
6 months all-cause mortality			
MPV (continuous variable)	0.90 (0.77, 1.06) 0.1920	0.90 (0.77, 1.06) 0.2054	0.94 (0.78, 1.13) 0.4888
MPV (grouped by quartile)			
Q1	Ref	Ref	Ref
Q2	0.83 (0.41, 1.66) 0.5955	0.82 (0.41, 1.65) 0.5753	0.69 (0.32, 1.51) 0.3554
Q3	0.49 (0.22, 1.10) 0.0839	0.48 (0.21, 1.08) 0.0758	0.49 (0.20, 1.18) 0.1098
Q4	0.76 (0.38, 1.56) 0.4585	0.78 (0.38, 1.59) 0.4883	0.94 (0.42, 2.07) 0.8734
P for trend	0.2663	0.2787	0.6522

Abbreviation:

RR: Relative risk

CI: Confidence interval

Non-adjusted model: No covariates were adjusted for

Minimally-adjusted model: We only adjusted for age and sex

Fully-adjusted model: We adjusted for all covariates presented in table 1.

medRxiv preprint doi: <https://doi.org/10.1101/2023.06.16.23291510>; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).

Table 3: Exploring the non-linear relationship between MPV and all-cause mortality

BMI (kg/m ²) grouping	<28	>=28	Total
Fitting model by standard binary	1.03 (0.83, 1.27)	1.00 (0.00, Inf)	1.01 (0.81, 1.25)
logistic regression model	0.8177	1.0000	0.9558
Fitting model by two-piecewise linear model			
Inflection point(95%CI)	9.7	9.4	9.8
	0.08 (0.03, 0.22)	1.00 (0.00, Inf)	0.09 (0.03, 0.24)
< inflection point	<0.0001	1.0000	<0.0001
> inflection point	1.29 (1.02, 1.64)	1.00 (0.00, Inf)	1.27 (1.01, 1.61)
	0.0334	1.0000	0.0434
P for log likelihood ratio test	<0.001	1.000	<0.001

medRxiv preprint doi: <https://doi.org/10.1101/2023.06.16.23291510>; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

We adjusted for all covariates presented in table 1.